■ LECTURE OVERVIEW: Hodgkin Lymphoma is a clonal B-cell malignancy characterized by the presence of pathognomonic giant tumor cells in a polymorphic background of reactive immune cells.
■ PATHOGNOMONIC HISTOLOGY & FLOW:
1. Giant Tumor Cells: The diagnostic hallmark is the Reed-Sternberg (RS) cell—a giant cell (20-40 microns) with abundant pale cytoplasm.
2. Owl Eyes: RS cells typically possess a bilobed or multilobed nucleus, with each lobe containing an extraordinarily prominent, acidophilic (pink) nucleolus surrounded by a clear halo, creating a classic 'owl-eye' appearance.
3. B-Cell Rearrangements: Though arising from mutated B-lineage cells in germinal centers, RS cells have lost their classical B-cell surface markers (such as CD20 and surface immunoglobulins).
4. Immunophenotype: Diagnostic RS cells are immunophenotypically positive for CD15 and CD30 but negative for CD45.
■ THERAPEUTIC TARGETS & MANAGEMENT:
Primary pharmacological intervention aims to restore physiological homeostatic balance. This is achieved by either competitively blocking receptor sites, allosterically inhibiting enzymes, or supplementing missing metabolic products.
■ PHARMACODYNAMIC TARGET ENGAGEMENT:
Receptor binding dynamics dictate the overall speed, duration, and magnitude of physiological responses to therapeutic agents.
[HY-BOARD-1364]
🌟 Dynamic Clinical Key:
Classic Hodgkin Lymphoma peaks in young adults (bimodal age distribution: 15-35 and >55 years). It typically presents with painless cervical lymphadenopathy and systemic 'B symptoms' (fever, night sweats, weight loss) driven by systemic cytokine release from tumor cells. Absolute contraindications include pregnancy, renal insufficiency, or concurrent use of metabolic inhibitors. Watch closely for ligand-receptor saturation effects and subsequent tolerance or resistance.